E7 protein (Human papillomavirus type 18) (HPV-18 E7)

The HPV-18 E7 protein is a viral oncoprotein produced by high-risk human papillomavirus type 18 that plays a central role in cervical cancer development. The protein is composed of three conserved regions (CR1, CR2, and CR3), with CR3 forming a zinc-coordinated homodimeric domain that mediates critical protein-protein interactions. E7 drives transformation and tumorigenesis through multiple mechanisms: it binds and inactivates the retinoblastoma tumor suppressor protein (pRb), promotes proteasomal degradation of protein tyrosine phosphatase 14 (PTPN14), and disrupts cell cycle checkpoints, thereby forcing quiescent cells into the cell cycle and promoting proliferation, migration, and invasion. The E7-PTPN14 interaction specifically leads to dysregulation of Hippo signaling, a key pathway controlling cell proliferation. As a viral oncoprotein that is essential for HPV persistence and malignant progression, HPV-18 E7 represents a potential therapeutic target, though direct pharmacological targeting remains investigational and faces challenges given the protein's multiple cellular interaction partners and the complexity of its oncogenic mechanisms.

Other names

E7 oncoproteinHPV18 E7Transforming protein E7

HPV-18 E7 promotes tumorigenesis through multiple pathways: (1) binding and promoting proteasomal degradation of PTPN14 (protein tyrosine phosphatase 14), leading to dysregulation of Hippo signaling and enhanced cell proliferation and invasion; (2) binding to and inactivating the retinoblastoma tumor suppressor protein (pRb) via its CR2 conserved region; (3) disruption of cell cycle checkpoints through manipulation of CDK2 complexes and inhibitors of cyclic-dependent kinases; (4) evasion of apoptosis and senescence through multiple molecular interactions.